Table 4.
Site of incident detection of type-specific infections with clinically-relevant HPV types,a by circumcision status.
| Site of Incident HPV Detection |
No. Infections Among Circumsized Subjects (% of Total Incident Infections Among Circumsized Subjects) |
No. Infections Among Uncircumsized Subjects (% of Total Incident Infections Among Uncircumsized Subjects) |
No. Infections Among All Subjects (% of Total Incident Infections Among All Subjects) |
|---|---|---|---|
| Urine Only | 21 (4.2) | 7 (4.2) | 28 (4.2) |
| Glans Only | 100 (20.0) | 51 (30.9) | 151 (22.7) |
| Shaft/Scrotum Only | 251 (50.2) | 49 (29.7) | 300 (45.1) |
| Urine & Glans | 1 (0.2) | 0 | 1 (0.2) |
| Urine & Shaft/Scrotum | 2 (0.4) | 0 | 2 (0.3) |
| Glans & Shaft/Scrotum | 120 (24.0) | 45 (27.3) | 165 (24.8) |
| All Sites | 5 (1.0) | 13 (7.9) | 18 (2.7) |
| Total Incident Infections | 500 (100) | 165 (100) | 665 (100) |
a
Clinically-relevant types were defined as high or probable high-risk types (HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82, and IS39, as defined in the cervical cancer literature) plus HPV6 and HPV11.